


Immune evasion strategies of HSV and the potential value of developing mRNA candidate vaccines against HSV

Akiko Iwasaki, Ph.D.

Immunobiology, Yale University

Howard Hughes Medical Institute

Female reproductive tract: portal of entry for sexually transmitted pathogens



- Women's health is severely understudied
- Huge human costs in the developing world

Human immunodeficiency virus 1

Human Papillomaviruses

Herpes simplex virus 2

Antiviral immune responses in the genital tract: clues for vaccines


Akiko Iwasaki

NATURE REVIEWS | IMMUNOLOGY


VOLUME 10 | OCTOBER 2010 | 699

Fig. 2. Map of regional estimates of the number and prevalence of herpes simplex virus type 2 infections in females and males, 2016


- ~half a billion people had genital infection with HSV type 2
- More women (313.5 million) than men (178.0 million) were infected.
- ~3.6 billion had oral HSV type 1 infection.



Stages of herpes simplex virus infection



HSV-1 and HSV-2 use immunoevasins to escape antibody-dependent clearance



gC binds the complement C3 and inhibits complement-mediated virus neutralization and the lysis of infected cells.


gE/gI complex acts as an FcR decoy on the viral envelope

AR Iwasaki A. 2016.
Annu. Rev. Immunol. 34:575–608


Major challenges

- Most vaccines rely on antibodies.
- HSVs evade antibody responses.
- Most infections start locally in a tissue.
- Current vaccines fail to establish mucosa immunity.
- Do circulating memory T cells protect the host?

Do circulating memory T cells confer protection?




Circulating memory T cells only partially protect the host against HSV-2 challenge




T_{RM} secrete $IFN\gamma$ to block virus replication

Group #	Symbol		HSV-2 challenge	Number of mice
1	●	Naive WT	Naive WT	9
2	■	Immune WT	Immune WT	12
3	▲	Immune WT	Naive WT	20



Discovery of a new type of lymphoid structure; memory lymphocyte cluster


- Local viral infection establishes memory lymphocyte clusters.
- MLC is an organized outpost full of virus-specific T cells ready to defend against local viral challenge.





Memory lymphocyte cluster (MLC)

Prime and Pull Vaccine Strategy


Prime





Prime and Pull establishes tissue resident memory T cells




Prime and Pull protects mice from lethal herpes infection



Prime and Pull therapeutic vaccine cures existing disease



mRNA vaccines against HSV



NCT05432583: Phase 1 Clinical Trial in Healthy Volunteers to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

BNT163 candidate vaccine encodes three HSV-2 glycoproteins, gC, gD and gE to help prevent HSV cellular entry and spread and counteract the immunosuppressive properties of HSV.

PLOS PATHOGENS

OPEN ACCESS PEER-REVIEWED

RESEARCH ARTICLE

An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection

Kevin P. Egan, Lauren M. Hook, Alexis Naughton, Norbert Pardi, Sita Awasthi, Gary H. Cohen, Drew Weissman, Harvey M. Friedman

Version 2

Published: July 27, 2020 • <https://doi.org/10.1371/journal.ppat.1008795>

Moderna's herpes simplex virus (HSV) vaccine candidate (mRNA-1608)

Final thoughts

mRNA or any other vaccine approaches against genital herpes might benefit from incorporating the Prime and Pull approaches to inducing robust mucosal immunity.

Other strategies to recruit T and B cells to the genital mucosa can be combined with conventional mRNA vaccines to prevent and treat genital herpes.